New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
07:41 EDTSNYSanofi R&D focused on biology of disease, WSJ reports
Dr. Elias Zerhouni, a former director of the U.S. National Institutes of Health, and now head of R&D at Sanofi (SNY) is attempting to shift to an earlier stage of research and development, and boost the number and quality of the company's drug discoveries. He has recruited about 20 new R&D leaders to help Sanofi become better at understanding how diseases work and how to target them. "We're investing a lot more upstream in understanding human-disease biology," he says. "We're extremely good at toolmaking," he added, referring to the formulation of new pills and shots, "but not very good at understanding the biology" of disease.Reference Link
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information
December 4, 2014
11:12 EDTSNYSanofi diabetes sales head left company, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use